ZAI LAB LIMITED - AMER

Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian Cancer

30 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces Upcoming Presentations at December Investor Conferences

23 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors

22 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in CIDP

16 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Pemphigus

15 Nov 2021 07:30:01 By Nasdaq GlobeNewswire

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune Thrombocytopenia

11 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces Third Quarter 2021 Financial Results and Corporate Updates

09 Nov 2021 16:10:57 By Nasdaq GlobeNewswire

Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China

09 Nov 2021 08:00:03 By Nasdaq GlobeNewswire

Zai Lab and Karuna Therapeutics Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

09 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Zai Lab Announces Upcoming Presentations in November Investor Conferences

04 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Zai Lab to Announce Third Quarter 2021 Financial Results

26 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces First Patient Treated in Greater China Portion of Potentially Registrational, Global Phase 2 Study of Odronextamab

25 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

ZL-1102, Zai Lab’s Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psoriasis Study

20 Oct 2021 16:05:00 By Nasdaq GlobeNewswire

Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial

19 Oct 2021 09:00:03 By Nasdaq GlobeNewswire

Zai Lab Appoints Scott Morrison to its Board of Directors

18 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces Upcoming Presentations in October Investor Conferences

11 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces Margetuximab Achieved Primary Objective in Bridging Study in Advanced HER2+ Breast Cancer in Greater China

05 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors

04 Oct 2021 09:10:00 By Nasdaq GlobeNewswire

Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

04 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Holds Virtual Research and Development Day

22 Sep 2021 12:22:00 By Nasdaq GlobeNewswire